{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:15:40Z","timestamp":1778717740615,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04943-9","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:05:14Z","timestamp":1775232314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of treatment-switch to telitacicept in high-risk IgA nephropathy: an observational case series of two clinical scenarios"],"prefix":"10.1186","volume":"27","author":[{"given":"Jiangyuan","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chendan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"2","key":"4943_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2010","unstructured":"McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transpl. 2010;26(2):414\u201330.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4943_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Semin Nephrol. 2018;38(5):435\u201342.","journal-title":"Semin Nephrol"},{"issue":"6","key":"4943_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s40620-025-02261-1","volume":"38","author":"L Xu","year":"2025","unstructured":"Xu L, Wu C, Li G. Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review. J Nephrol. 2025;38(6):1557\u201364.","journal-title":"J Nephrol"},{"key":"4943_CR4","doi-asserted-by":"crossref","unstructured":"Lai KN, Tang SCW, Schena FP, Novak J, Tomino Y, Fogo AB, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2(1).","DOI":"10.1038\/nrdp.2016.1"},{"key":"4943_CR5","doi-asserted-by":"crossref","unstructured":"Ouyang Y, Zhao Z, Li G, Luo H, Xu F, Shao L, et al. A validation study comparing risk prediction models of IgA nephropathy. Front Immunol. 2021;12.","DOI":"10.3389\/fimmu.2021.753901"},{"issue":"3","key":"4943_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1053\/j.ajkd.2018.01.043","volume":"72","author":"J Xie","year":"2018","unstructured":"Xie J, Lv J, Wang W, Li G, Liu Z, Chen H, et al. Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients. Am J Kidney Dis. 2018;72(3):371\u201380.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4943_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1\u2013276.","journal-title":"Kidney Int"},{"key":"4943_CR8","doi-asserted-by":"crossref","unstructured":"Di Leo V, Annese F, Papadia F, Russo MS, Giliberti M, Sallustio F, et al. Refractory IgA nephropathy: a challenge for future nephrologists. Med (Kaunas). 2024;60(2).","DOI":"10.3390\/medicina60020274"},{"issue":"4","key":"4943_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","volume":"108","author":"BH Rovin","year":"2025","unstructured":"Rovin BH, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, et al. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4):S1\u201371.","journal-title":"Kidney Int"},{"issue":"1","key":"4943_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10157-018-1582-2","volume":"23","author":"H Suzuki","year":"2018","unstructured":"Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2018;23(1):26\u201331.","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"4943_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s00108-018-0443-0","volume":"59","author":"R Bollin","year":"2018","unstructured":"Bollin R, Haller H. Pathophysiologie und Therapie der IgA-Nephropathie. Internist (Berl). 2018;59(7):736\u201340.","journal-title":"Internist (Berl)"},{"issue":"7","key":"4943_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ki.2012.197","volume":"82","author":"N Zhao","year":"2012","unstructured":"Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012;82(7):790\u20136.","journal-title":"Kidney Int"},{"issue":"3","key":"4943_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/ndt\/gfaa264","volume":"36","author":"F Sallustio","year":"2021","unstructured":"Sallustio F, Curci C, Chaoul N, Font\u00f2 G, Lauriero G, Picerno A, et al. High levels of gut-homing immunoglobulin A\u2009+\u2009B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients. Nephrol Dial Transpl. 2021;36(3):452\u201364.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4943_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","volume":"36","author":"E Samy","year":"2017","unstructured":"Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3\u201319.","journal-title":"Int Rev Immunol"},{"issue":"5","key":"4943_CR15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1172\/JCI38010","volume":"119","author":"MP Cancro","year":"2009","unstructured":"Cancro MP, D\u2019Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066\u201373.","journal-title":"J Clin Invest"},{"issue":"14","key":"4943_CR16","first-page":"1671","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S, Telitacicept. First Approval Drugs. 2021;81(14):1671\u20135.","journal-title":"First Approval Drugs"},{"issue":"6","key":"4943_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43(6):666\u201373.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"4943_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P, Xing G, et al. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney Int Rep. 2023;8(3):499\u2013506.","journal-title":"Kidney Int Rep"},{"issue":"10","key":"4943_CR19","first-page":"914","volume":"64","author":"SF Shi","year":"2025","unstructured":"Shi SF, Lyu JC, Zhang H. [Interpretation of the clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)]. Zhonghua nei ke za zhi. 2025;64(10):914\u20137.","journal-title":"Zhonghua nei ke za zhi"},{"issue":"1","key":"4943_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492237","volume":"149","author":"L Liu","year":"2025","unstructured":"Liu L, Liu Y, Li J, Tang C, Wang H, Chen C, et al. Efficacy and Safety of Telitacicept in IgA Nephropathy: A Retrospective, Multicenter Study. Nephron. 2025;149(1):1\u201310.","journal-title":"Nephron"},{"issue":"1","key":"4943_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13075-025-03581-0","volume":"27","author":"K Kojima","year":"2025","unstructured":"Kojima K, Ichinose K, Umeda M, Shimizu T, Sato S, Suzuki T, et al. Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years. Arthritis Res Ther. 2025;27(1):116.","journal-title":"Arthritis Res Ther"},{"key":"4943_CR22","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"issue":"10405","key":"4943_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370.","journal-title":"Lancet"},{"issue":"2","key":"4943_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391\u2013402.","journal-title":"Kidney Int"},{"issue":"1","key":"4943_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh K-H, et al. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med. 2024;390(1):20\u201331.","journal-title":"N Engl J Med"},{"key":"4943_CR26","doi-asserted-by":"crossref","unstructured":"Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, et al. Sibeprenlimab in IgA nephropathy \u2014 interim analysis of a phase 3 trial. N Engl J Med. 2026;394(7):635\u201346.","DOI":"10.1056\/NEJMoa2512133"},{"issue":"6","key":"4943_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306\u201315.","journal-title":"Kidney Int"},{"issue":"8","key":"4943_CR28","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00467-025-06769-3","volume":"40","author":"Y Jin","year":"2025","unstructured":"Jin Y, Zhu J, Sheng A, Lin Q, Zhao M, He X, et al. Telitacicept as a BAFF\/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. Pediatr Nephrol. 2025;40(8):2561\u20139.","journal-title":"Pediatr Nephrol"},{"key":"4943_CR29","doi-asserted-by":"crossref","unstructured":"Cai J, Gao D, Liu D, Liu Z. Telitacicept for autoimmune nephropathy. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1169084"},{"issue":"4","key":"4943_CR30","first-page":"283","volume":"24","author":"L Zhu","year":"2025","unstructured":"Zhu L, Chen P, Lv J. Clinical observation on the efficacy and safety of telitacicept in treatment of IgA nephropathy. Chin J Blood Purif. 2025;24(4):283\u20137.","journal-title":"Chin J Blood Purif"},{"issue":"12","key":"4943_CR31","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177\u201383.","journal-title":"J Am Soc Nephrol"},{"key":"4943_CR32","doi-asserted-by":"crossref","unstructured":"Xu Y, Mo Y, Xu Y. Advances in novel biologics targeting BAFF\/APRIL in the treatment of IgA nephropathy. Cells. 2026;15(3).","DOI":"10.3390\/cells15030240"},{"key":"4943_CR33","doi-asserted-by":"publisher","unstructured":"Weng Q, Zhu X, Ren H, Li X, Xie J. Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy. Nephrol Dial Transpl. 2026:gfag001. https:\/\/doi.org\/10.1093\/ndt\/gfag001. Epub ahead of print. PMID: 41524180","DOI":"10.1093\/ndt\/gfag001"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04943-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04943-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04943-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:58Z","timestamp":1778716858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04943-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4943"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04943-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and received approval from the Institutional Review Board of Shanxi Provincial People\u2019s Hospital, Shanxi Medical University(NO.2025\u2009\u2212\u2009722). Written informed consent was obtained from each patient involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}